Navarra P - Search Results

1

Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.

Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A. Fabbiani M, et al. Among authors: navarra p. J Antimicrob Chemother. 2009 Jul;64(1):109-17. doi: 10.1093/jac/dkp132. Epub 2009 Apr 27. J Antimicrob Chemother. 2009. PMID: 19398461

2

Function of the hypothalamo-pituitary-adrenal axis and humoral immune mechanisms during experimental allergic encephalomyelitis in SJL/J mice.

Andreini I, Getuli C, Pacelli V, Manno R, Ragazzoni E, Nunziata A, Navarra P. Andreini I, et al. Among authors: navarra p. Neuroimmunomodulation. 2002;10(1):9-16. doi: 10.1159/000064410. Neuroimmunomodulation. 2002. PMID: 12207159

3

Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.

Pinnetti C, Tamburrini E, Ragazzoni E, De Luca A, Navarra P. Pinnetti C, et al. Among authors: navarra p. Antivir Ther. 2010;15(1):127-9. doi: 10.3851/IMP1473. Antivir Ther. 2010. PMID: 20167999

4

Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, D'Ettorre G, Parruti G, Prosperi M, Bracciale L, Cauda R, Navarra P, De Luca A. Fabbiani M, et al. Among authors: navarra p. Pharmacol Res. 2011 Mar;63(3):249-53. doi: 10.1016/j.phrs.2010.11.009. Epub 2010 Dec 2. Pharmacol Res. 2011. PMID: 21130167

5

Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.

Fabbiani M, Bracciale L, Doino M, D'Avino A, Marzocchetti A, Navarra P, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: navarra p. J Infect. 2011 Apr;62(4):319-21. doi: 10.1016/j.jinf.2011.02.004. Epub 2011 Feb 15. J Infect. 2011. PMID: 21329725 Clinical Trial. No abstract available.

6

Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.

Dello Russo C, Lisi L, Lofaro A, Di Giambenedetto S, Federico B, Madeddu G, Salerno M, Mura MS, Pirazzoli A, de Luca A, Cauda R, Navarra P. Dello Russo C, et al. Among authors: navarra p. Pharmacogenomics. 2011 Apr;12(4):567-76. doi: 10.2217/pgs.10.208. Pharmacogenomics. 2011. PMID: 21521028

7

Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.

Lisi L, Tramutola A, De Luca A, Navarra P, Dello Russo C. Lisi L, et al. Among authors: navarra p. J Neurochem. 2012 Jan;120(1):106-14. doi: 10.1111/j.1471-4159.2011.07549.x. Epub 2011 Nov 17. J Neurochem. 2012. PMID: 22017448 Free article.

8

Is there a drug-drug interaction between darunavir/ritonavir and raltegravir?

Fabbiani M, Navarra P, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: navarra p. J Acquir Immune Defic Syndr. 2012 May 1;60(1):e18-20. doi: 10.1097/QAI.0b013e31824dd76d. J Acquir Immune Defic Syndr. 2012. PMID: 22517418 No abstract available.

9

Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).

Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Di Giambenedetto S, et al. Among authors: navarra p. J Antimicrob Chemother. 2013 Jun;68(6):1364-72. doi: 10.1093/jac/dkt007. Epub 2013 Jan 30. J Antimicrob Chemother. 2013. PMID: 23372058

10

Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samples.

Fortuna S, Ragazzoni E, Lisi L, Di Giambenedetto S, Fabbiani M, Navarra P. Fortuna S, et al. Among authors: navarra p. Ther Drug Monit. 2013 Apr;35(2):258-63. doi: 10.1097/FTD.0b013e318280110d. Ther Drug Monit. 2013. PMID: 23407478

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters